Moreover, among 125 NSCLC patients with EGFR genetic alteration information (Table S2), YAP1 protein expression level was higher in EGFR-mutant patients than in EGFR wild-type patients (Figure 1F, I), and YAP1 protein was also elevated in the patients with EGFR-TKI treatment (Figure 1H). This evidence concerns the gene EGFR and non-small cell lung carcinoma.